Lamotrigine Viatris 100 mg tablets

Lamotrigine Viatris is a generic pharmaceutical product used primarily for the treatment of epilepsy and bipolar disorder. The brand Viatris was established in November 2020 through the merger of Mylan and Upjohn, which was a legacy division of Pfizer. This strategic combination created a global healthcare powerhouse focused on providing high-quality medicines across a wide range of therapeutic areas.

While the brand is headquartered in the United States, its manufacturing operations are highly diversified to serve global markets. Specifically for Lamotrigine, production often takes place in facilities across Europe and India, including sites in Hungary (Mylan Hungary Kft.) and Ireland, as well as several plants in India. This decentralized manufacturing model ensures that the medication is accessible to patients worldwide.

Ownership of the brand lies with Viatris Inc., a publicly traded corporation on the NASDAQ. The company maintains a strong global presence with significant operations in North America, Europe, and Asia. It continues to operate as an independent entity, focusing on expanding access to affordable generics and innovative branded products.